Does the media favor CLLS or PLRX?

In the previous week, Cellectis had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Cellectis and 1 mentions for Pliant Therapeutics. Cellectis' average media sentiment score of 0.50 beat Pliant Therapeutics' score of 0.00 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PLRX or NMRA more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Neumora Therapeutics N/A -181.70% -119.15%

Pliant Therapeutics (PLRX) Competitors

$1.17 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.17 +0.00 (+0.09%)

As of 07/2/2026 06:56 PM Eastern

Compare

PLRX vs. CLLS, NMRA, BCYC, LYEL, and TRDA

Should you buy Pliant Therapeutics stock or one of its competitors? MarketBeat compares Pliant Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pliant Therapeutics include Cellectis (CLLS), Neumora Therapeutics (NMRA), Bicycle Therapeutics (BCYC), Lyell Immunopharma (LYEL), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry.

How does Pliant Therapeutics compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Pliant Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Pliant Therapeutics' return on equity of -58.11% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Pliant Therapeutics	N/A	-58.11%	-44.37%

In the previous week, Cellectis had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Cellectis and 1 mentions for Pliant Therapeutics. Cellectis' average media sentiment score of 0.50 beat Pliant Therapeutics' score of 0.00 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectis has higher revenue and earnings than Pliant Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$68.07M	4.86	-$67.59M	-$0.67	N/A
Pliant Therapeutics	$1.58M	45.85	-$149.34M	-$1.84	N/A

63.9% of Cellectis shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 8.0% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cellectis presently has a consensus price target of $7.00, suggesting a potential upside of 112.12%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 156.41%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Cellectis has a beta of 2.88, meaning that its share price is 188% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Summary

Cellectis beats Pliant Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Pliant Therapeutics compare to Neumora Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for Neumora Therapeutics. Pliant Therapeutics' average media sentiment score of 0.00 equaled Neumora Therapeutics'average media sentiment score.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Neumora Therapeutics	Neutral

Pliant Therapeutics' return on equity of -58.11% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Pliant Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	45.85	-$149.34M	-$1.84	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Pliant Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market.

Pliant Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 156.41%. Neumora Therapeutics has a consensus price target of $6.86, indicating a potential upside of 310.61%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 8.0% of Pliant Therapeutics shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Pliant Therapeutics and Neumora Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Bicycle Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.00 equaled Pliant Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
Pliant Therapeutics	Neutral

Pliant Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Bicycle Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 221.84%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 156.41%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Pliant Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$63.50M	4.78	-$218.96M	-$3.15	N/A
Pliant Therapeutics	$1.58M	45.85	-$149.34M	-$1.84	N/A

Summary

Bicycle Therapeutics beats Pliant Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Lyell Immunopharma?

Pliant Therapeutics (NASDAQ:PLRX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.00 beat Pliant Therapeutics' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Lyell Immunopharma	Positive

Pliant Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Pliant Therapeutics' return on equity of -58.11% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pliant Therapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	45.85	-$149.34M	-$1.84	N/A
Lyell Immunopharma	$40K	8,194.66	-$274.45M	-$13.80	N/A

Pliant Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 156.41%. Lyell Immunopharma has a consensus price target of $43.00, suggesting a potential upside of 206.05%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Pliant Therapeutics beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.

How does Pliant Therapeutics compare to Entrada Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Pliant Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Pliant Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 156.41%. Entrada Therapeutics has a consensus target price of $17.50, indicating a potential upside of 126.68%. Given Pliant Therapeutics' higher probable upside, equities analysts plainly believe Pliant Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Entrada Therapeutics has higher revenue and earnings than Pliant Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	45.85	-$149.34M	-$1.84	N/A
Entrada Therapeutics	$25.42M	11.79	-$143.75M	-$3.99	N/A

In the previous week, Pliant Therapeutics had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for Entrada Therapeutics. Pliant Therapeutics' average media sentiment score of 0.00 equaled Entrada Therapeutics'average media sentiment score.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Entrada Therapeutics	Neutral

Pliant Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

Summary

Pliant Therapeutics beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$72.45M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.64	21.61	28.02	24.70
Price / Sales	45.85	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.40	8.66	10.96	6.46
Net Income	-$149.34M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.63%	3.39%	2.12%	1.69%
1 Month Performance	1.74%	10.81%	5.25%	3.81%
1 Year Performance	-6.02%	62.61%	33.29%	23.90%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.0239 of 5 stars	$1.17 flat	$3.00 +156.4%	-6.0%	$72.45M	$1.58M	N/A	90	Gap Down High Trading Volume
CLLS Cellectis	2.4494 of 5 stars	$2.86 -4.0%	$7.00 +144.8%	+108.2%	$286.97M	$68.07M	N/A	290	Gap Down
NMRA Neumora Therapeutics	3.7478 of 5 stars	$1.54 +0.3%	$6.86 +346.7%	+105.9%	$284.41M	N/A	N/A	108	Gap Down
BCYC Bicycle Therapeutics	3.0528 of 5 stars	$4.06 +1.9%	$14.00 +245.3%	-41.4%	$282.74M	$63.50M	N/A	240
LYEL Lyell Immunopharma	3.7512 of 5 stars	$11.98 -6.0%	$43.00 +259.1%	+49.2%	$279.38M	$40K	N/A	270	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. CLLS, NMRA, BCYC, LYEL, and TRDA

How does Pliant Therapeutics compare to Cellectis?

Summary

How does Pliant Therapeutics compare to Neumora Therapeutics?

Summary

How does Pliant Therapeutics compare to Bicycle Therapeutics?

Summary

How does Pliant Therapeutics compare to Lyell Immunopharma?

Summary

How does Pliant Therapeutics compare to Entrada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. CLLS, NMRA, BCYC, LYEL, and TRDA

How does Pliant Therapeutics compare to Cellectis?

Is CLLS or PLRX more profitable?

Does the media favor CLLS or PLRX?

Which has preferable valuation and earnings, CLLS or PLRX?

Do insiders & institutionals believe in CLLS or PLRX?

Do analysts prefer CLLS or PLRX?

Which has more risk & volatility, CLLS or PLRX?

Summary

How does Pliant Therapeutics compare to Neumora Therapeutics?

Does the media refer more to PLRX or NMRA?

Is PLRX or NMRA more profitable?

Which has higher valuation and earnings, PLRX or NMRA?

Which has more volatility & risk, PLRX or NMRA?

Do analysts recommend PLRX or NMRA?

Do institutionals & insiders believe in PLRX or NMRA?

Summary

How does Pliant Therapeutics compare to Bicycle Therapeutics?

Which has more risk and volatility, BCYC or PLRX?

Do institutionals and insiders hold more shares of BCYC or PLRX?

Does the media favor BCYC or PLRX?

Is BCYC or PLRX more profitable?

Do analysts recommend BCYC or PLRX?

Which has higher earnings & valuation, BCYC or PLRX?

Summary

How does Pliant Therapeutics compare to Lyell Immunopharma?

Does the media refer more to PLRX or LYEL?

Is PLRX or LYEL more profitable?

Do insiders & institutionals have more ownership in PLRX or LYEL?

Which has preferable valuation & earnings, PLRX or LYEL?

Which has more risk and volatility, PLRX or LYEL?

Do analysts recommend PLRX or LYEL?

Summary

How does Pliant Therapeutics compare to Entrada Therapeutics?

Is PLRX or TRDA more profitable?

Do analysts rate PLRX or TRDA?

Do institutionals & insiders believe in PLRX or TRDA?

Which has better valuation and earnings, PLRX or TRDA?

Does the media favor PLRX or TRDA?

Which has more risk and volatility, PLRX or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools